Riverwater Partners LLC lifted its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 21.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 60,628 shares of the biotechnology company’s stock after buying an additional 10,542 shares during the period. Exelixis comprises 1.0% of Riverwater Partners LLC’s portfolio, making the stock its 22nd biggest holding. Riverwater Partners LLC’s holdings in Exelixis were worth $2,657,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in EXEL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Exelixis by 81.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock worth $1,592,000 after purchasing an additional 19,407 shares during the period. Goldman Sachs Group Inc. lifted its stake in Exelixis by 4.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock worth $54,153,000 after purchasing an additional 68,133 shares during the period. Focus Partners Wealth lifted its stake in Exelixis by 83.4% during the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock worth $1,420,000 after purchasing an additional 17,483 shares during the period. Geneos Wealth Management Inc. lifted its stake in Exelixis by 134.3% during the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 944 shares during the period. Finally, Sivia Capital Partners LLC lifted its stake in Exelixis by 23.8% during the second quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock worth $633,000 after purchasing an additional 2,764 shares during the period. Institutional investors own 85.27% of the company’s stock.
Exelixis Trading Up 1.7%
NASDAQ EXEL opened at $53.50 on Friday. The firm has a market cap of $13.45 billion, a price-to-earnings ratio of 17.77, a PEG ratio of 1.52 and a beta of 0.41. The company has a 50 day moving average of $47.80 and a 200-day moving average of $44.83. Exelixis, Inc. has a 1-year low of $33.76 and a 1-year high of $53.93.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on EXEL. Truist Financial upgraded shares of Exelixis to a “strong-buy” rating in a research note on Monday, April 27th. TD Cowen raised their price target on shares of Exelixis from $51.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Weiss Ratings restated a “buy (b)” rating on shares of Exelixis in a research note on Tuesday, May 19th. Wall Street Zen upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Stifel Nicolaus raised their price target on shares of Exelixis from $44.00 to $47.00 and gave the stock a “hold” rating in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Exelixis has an average rating of “Hold” and an average target price of $47.35.
Read Our Latest Stock Analysis on EXEL
Insider Activity at Exelixis
In other news, EVP Patrick J. Haley sold 32,110 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $49.81, for a total transaction of $1,599,399.10. Following the completion of the sale, the executive vice president owned 357,638 shares of the company’s stock, valued at approximately $17,813,948.78. This trade represents a 8.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Dana Aftab sold 43,451 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the sale, the executive vice president directly owned 594,741 shares of the company’s stock, valued at approximately $29,945,209.35. The trade was a 6.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 219,170 shares of company stock valued at $10,620,641. Insiders own 2.60% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.
The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.
Featured Stories
- Five stocks we like better than Exelixis
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.
